

## Publications by Justin Wilkins

### Peer-reviewed journal articles

- Kotani N, **Wilkins JJ**, Wade JR, Dang S, Sutaria DS, Yoshida K, Sundrani S, Ding H, Garcia J, Hinton H, Sane R, Chanu P. Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. *Cancer Chemother Pharmacol*. 2022 Dec;90(6):511-521. doi: 10.1007/s00280-022-04488-2. Epub 2022 Oct 28. PMID: 36305957; PMCID: PMC9637074.
- Khandelwal A, Arez F, Alves PM, Badolo L, Brito C, Fischli C, et al. Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside. *Malar J*. 2022;21(1):1–7.
- **Wilkins JJ**, Svensson EM, Ernest JP, Savic RM, Simonsson USH, McIlleron H. Pharmacometrics in tuberculosis: progress and opportunities. *Int J Antimicrob Agents*. 2022;(xxxx):106620. Available from: <https://doi.org/10.1016/j.ijantimicag.2022.106620>
- Zhu R, Owen R, **Wilkins J**, Schoemaker R, Tian X, Gautier A, et al. Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps. *Pulm Pharmacol Ther*. 2021 Dec 1;71:102080.
- Yoshida K, **Wilkins J**, Winkler J, Wade JR, Kotani N, Wang N, et al. Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. *J Clin Pharmacol*. 2021 Jul 17;61(12):1579–91. Available from: <https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.1942>
- Fidler M, Hooijmaijers R, Schoemaker R, **Wilkins JJ**, Xiong Y, Wang W. R and nlmixr as a gateway between statistics and pharmacometrics. *CPT Pharmacometrics Syst Pharmacol*. 2021 Apr 1;10(4):283–5.
- Vugmeyster Y, **Wilkins J**, Koenig A, El Bawab S, Dussault I, Ojalvo LS, et al. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$  and PD-L1. *Clin Pharmacol Ther*. 2020 Sep 1;108(3):566–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/31955412/>
- Novakovic AM, **Wilkins JJ**, Dai H, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. *Clin Pharmacol Ther*. 2020 107(3):588-596.
- **Wilkins JJ**. The guard changes. *J Pharmacokinet Pharmacodynam*. 2020; 47:3–4.
- Schoemaker R, Fidler M, Laveille C, **Wilkins JJ**, Hooijmaijers R, Post TM, Trame MN, Xiong Y, Wang W. Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixr. *CPT Pharmacometrics Syst Pharmacol*. 2019 8(12):923-930.
- **Wilkins JJ**, Vugmeyster Y, Dussault I, Girard P, Khandelwal A. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types. *Adv Ther*. 2019 36(9):2414-2433.
- Fidler M, **Wilkins JJ**, Hooijmaijers R, Post TM, Schoemaker R, Trame MN, Xiong Y, Wang W. Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages. *CPT Pharmacometrics Syst Pharmacol*. 2019 8(9):621-633.

- **Wilkins JJ**, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A. Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. *CPT Pharmacometrics Syst Pharmacol*. 2019 Jun;8(6):415-427.
- Radivojevic A, Corrigan B, Downie N, Fox R, Fiedler-Kelly J, Liu H, Melhem M, Radke D, Schaefer P, Su J, Swat MJ, Teuscher NS, Thanneer N, Zong A, **Wilkins JJ**. Data standards for model-informed drug development: an ISoP initiative. *J Pharmacokinet Pharmacodyn*. 2018 45(5):659-661.
- Conrado DJ, Karlsson MO, Romero K, Sarr C, **Wilkins JJ**. Open Innovation: towards sharing of data, models and workflows. *Eur J Pharm Sci*. 2017 109S:S65-S71.
- Chen P, Olsson Gisleskog P, Perez-Ruixo JJ, Xiao J, **Wilkins J**, Narayanan A, et al. Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis. *CPT Pharmacometrics Syst Pharmacol*. 2016 Sep 1;5(9):484–94. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/psp4.12106>
- **Wilkins JJ**, Chan PLS, Chard J, Smith G, Smith MK, Beer M, et al. Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and Development. *CPT Pharmacometrics Syst Pharmacol*. 2017;6(5):285–92.
- **Wilkins JJ**, Dubar M, Sébastien B, Laveille C. A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. *Journal of Clinical Pharmacology*, 2014; 54(3):267-78.
- Brennan BJ, Wang K, Blotner S, Magnusson MO, **Wilkins JJ**, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. *Antimicrob Agents Chemother*. 2013 Dec;57(12):6097-105
- Joerger, M, **Wilkins J**, Fagagnini S, Baldinger R., Brenneisen R, Schneider U, et al. Single-dose Pharmacokinetics and Tolerability of Oral Delta-9-Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis. *Drug Metabolism Letters*, 2012; 6(2), 102–108.
- **Wilkins JJ**, Langdon G, McIlleron H, Pillai GC, Smith PJ & Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. *British Journal of Clinical Pharmacology*, 2011; 72(1): 51–62.
- Jönsson S, Davidse A, **Wilkins J**, van der Walt JS, Simonsson US, Karlsson MO, Smith P, McIlleron H. Population pharmacokinetics of ethambutol in South African tuberculosis patients. *Antimicrob Agents Chemother*. 2011 Sep;55(9):4230-7
- Karlsson KE, **Wilkins JJ**, Jonsson F, Zingmark PH, Karlsson MO & Jonsson EN. Modeling disease progression in acute stroke using clinical assessment scales. *The AAPS Journal* 2010; 12(4), 683–691.
- Baverel PG, Savic RM, **Wilkins JJ**, Karlsson MO. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data. *J Pharmacokinet Pharmacodyn*. 2009 Aug;36(4):297-315
- **Wilkins JJ**, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. *Antimicrobial Agents and Chemotherapy* 2008; 52(6):2138-48.

- **Wilkins JJ**, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson USH. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. *European Journal of Clinical Pharmacology* 2006 Sep;62(9):727-35.
- **Wilkins JJ**. NONMEMory: A run management tool for NONMEM. *Computer Methods and Programs in Biomedicine* 2005; 78(3):259-67.
- Langdon G, **Wilkins JJ**, McFadyen L, McIlleron H, Smith PJ, Simonsson USH. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. *Antimicrobial Agents and Chemotherapy* 2005; 49(11):4429-36.
- Langdon G, **Wilkins J**, Smith P & McIlleron H. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. *International Journal of Tuberculosis and Lung Disease* 2004; 8(7):862-7.
- **Wilkins JJ**, Folb PI, Valentine N, Barnes KI. An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: development of a model for estimating recurrent direct costs. *Trans R Soc Trop Med Hyg.* 2002 Jan-Feb;96(1):85-90.
- Wilder-Smith CH, Hill L, **Wilkins J**, Denny L. Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery. *Anesthesiology.* 1999 Sep;91(3):639-47

## Conference Proceedings

- Kuiper V, van de Plas J, Yalkinoglu O, Tappert A, Yin X, Bezuidenhout D, et al. The Plasmodium falciparum Elongation Factor 2 Inhibitor M5717 is Efficacious Against Malaria Liver Stage: A Controlled Liver-Stage Malaria Infection Study in Healthy Subjects. *American Society of Tropical Medicine & Hygiene Annual Meeting*, November 17-21 2021, online.
- McCarthy J, Yalkinoglu O, Odedra A, Webster R, Ouevray C, Tappert A, Bezuidenhout D, **Wilkins J**, Khandelwal A, Bagchus W. A Phase IA, First-in-Human, Dose-Escalation Study of M5717: A First-in-Class Inhibitor of Plasmodium falciparum Eukaryotic Translation Elongation Factor 2 [Abstract 1591]. *American Society of Tropical Medicine & Hygiene Annual Meeting*, November 20-24 2019, National Harbor, Maryland, USA.
- Dai H, Novakovic AM, **Wilkins JJ**, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A. M-054. From weight-based dose to flat dose, modeling and simulation justification for the avelumab dosing regimen. *ACoP10* (2019).
- Schoemaker S, Fidler M, Laveille C, **Wilkins JJ**, Hooijmaijers R, Post TM, Trame MN, Xiong Y, Wang W. Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr. *PAGE 28* (2019) Abstr 8978 [[www.page-meeting.org/?abstract=8978](http://www.page-meeting.org/?abstract=8978)]
- **Wilkins JJ**, Bagchus W, Yalkinoglu O, Ouevray C, McCarthy J, Khandelwal A. Population Pharmacokinetics analysis of M5717, a novel antimalarial agent. *PAGE 28* (2019) Abstr 9044 [[www.page-meeting.org/?abstract=9044](http://www.page-meeting.org/?abstract=9044)]
- **Wilkins JJ**, Koenig A, Klopp-Schulze L, Vugmeyer Y, De Banerjee S, Ojalvo LS, Girard P, Khandelwal A. Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development. *PAGE 28* (2019) Abstr 9086 [[www.page-meeting.org/?abstract=9086](http://www.page-meeting.org/?abstract=9086)]

- Fidler M, Xiong Y, Schoemaker R, **Wilkins J**, Trame MN, Post T, Hooijmaijers R, Wang W. W-058. Exploring inductive linearization in population pharmacokinetic and pharmacodynamic models. Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9). J Pharmacokinet Pharmacodyn. 2018 45(S1):S116.
- Hooijmaijers R, Fidler M, Schoemaker R, Trame MN, Wang W, **Wilkins JJ**, Xiong Y, Post TM. ShinyMixR: A project-centric R/Shiny run management tool for nlmixr. PAGE 27 (2018) Abstr 8452 [[www.page-meeting.org/?abstract=8452](http://www.page-meeting.org/?abstract=8452)]
- **Wilkins JJ**, Vugmeyster Y, Dussault I, Terranova N, Khandelwal A. Population pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer types. PAGE 27 (2018) Abstr 8499 [[www.page-meeting.org/?abstract=8499](http://www.page-meeting.org/?abstract=8499)]
- Novakovic AM, **Wilkins J**, Dai H, Brar S, Bello CL, Neuteboom B, Girard P, Khandelwal A. Simulation based assessment of flat dose regimen of an anti-PDL1 antibody: Case study of avelumab. PAGE 27 (2018) Abstr 8678 [[www.page-meeting.org/?abstract=8678](http://www.page-meeting.org/?abstract=8678)]
- Schoemaker R, Fidler M, Xiong Y, **Wilkins J**, Trame MN, Laveille C, Wang W. T-012. nlmixr: an open-source package for pharmacometric modelling in R. Abstracts for American Conference on Pharmacometrics 2017 (ACoP8). J Pharmacokinet Pharmacodyn. 2017 44(S1):S60.
- **Wilkins J**, Wang S, Brockhaus B, Dai H, Vugmeyster Y, Neuteboom B, Brar S, Bello C, Wade JR, Khandelwal A, Girard P. W-079. Clearance over time and effect of response in the pharmacokinetics of avelumab. Abstracts for American Conference on Pharmacometrics 2017 (ACoP8). J Pharmacokinet Pharmacodyn. 2017 44(S1):S132.
- **Wilkins J**, Brockhaus B, Wang S, Dai H, Vugmeyster Y, Neuteboom B, Brar S, Bello C, Wade JR, Khandelwal A, Girard P. W-080. Population pharmacokinetic analysis of avelumab in different cancer types. Abstracts for American Conference on Pharmacometrics 2017 (ACoP8). J Pharmacokinet Pharmacodyn. 2017 44(S1):S133.
- Schoemaker R, Fidler M, Xiong Y, **Wilkins J**, Trame M, Laveille C, Wang W. nlmixr: an open-source package for pharmacometric modelling in R. PAGE 26 (2017) Abstr 7102 [[www.page-meeting.org/?abstract=7102](http://www.page-meeting.org/?abstract=7102)]
- Chard J, **Wilkins J**, Cheung A, Wang E, Smith MK, Chan P, Sardu ML. T-32. Pharmacometrics “Thoughtflow”: Standards for provenance capture and workflow definition. Abstracts accepted for American Conference on Pharmacometrics 2016 (ACoP7). J Pharmacokinet Pharmacodyn. 2016 43(S1):S62.
- Schoemaker R, Xiong Y, **Wilkins J**, Laveille C, Wang W. W-66. nlmixr: an open-source package for pharmacometric modelling in R. Abstracts accepted for American Conference on Pharmacometrics 2016 (ACoP7). J Pharmacokinet Pharmacodyn. 2016 43(S1):S115.
- Chard J, **Wilkins J**, Cheung A, Wang E, Smith MK, Chan P, Smith P, Kaye R, Sardu ML, Moodie S. Pharmacometrics workflow: standards for provenance capture and workflow definition. PAGE 25 (2016) Abstr 5792 [[www.page-meeting.org/?abstract=5792](http://www.page-meeting.org/?abstract=5792)]
- Melhem M, Olsson Gisleskog P, **Wilkins J**, Narayanan A, Chen P. W-16. Population Pharmacokinetics and Pharmacodynamics (PK/PD) of AMG 416 in Chronic Kidney Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (sHPT) Receiving Hemodialysis. Abstracts accepted for American Conference on Pharmacometrics 2015 (ACoP6). J Pharmacokinet Pharmacodyn. 2016 42(S1):S81
- Lindauer A, Elshoff, J-P, **Wilkins J**, Olsson Gisleskog P. A two-part mixed-effects model for semi-continuous data to describe the effect of transdermal rotigotine on restless legs symptoms in adults. PAGE 24 (2015) Abstr 3406 [[www.page-meeting.org/?abstract=3406](http://www.page-meeting.org/?abstract=3406)]

- **Wilkins JJ** & Jonsson EN. Reproducible pharmacometrics (tutorial). PAGE 22 (2013) Abstr 2774 [www.page-meeting.org/?abstract=2774]
- Brennan B, Magnusson MO, **Wilkins JJ**, Martin K, Nieforth K, Solsky J, Wat C. Population Pharmacokinetic (PK) Analysis of Ribavirin (Copegus) in Chronic Hepatitis C (CHC) Patients with Chronic Kidney Disease (CKD) Leads to Changes in Recommended Dosing [1093]. Abstracts of The International Liver Congress™ 2012 – 47th annual meeting of the European Association for the Study of the Liver. J Hepatol 2012;56(Suppl 2):S430.
- **Wilkins JJ** & Looby M. A comparison of two model-based approaches to investigating covariate effects on the dose-exposure relationship in a Phase III context. PAGE 19 (2010) Abstr 1751 [www.page-meeting.org/?abstract=1751]
- **Wilkins JJ**. Census: NLME project management for NONMEM. PAGE 18 (2009) Abstr 1473 [www.page-meeting.org/?abstract=1473]
- Wu K, Looby M, **Wilkins J**, Olsson Gislekog P, Renard D, Lemarechal MO, Pascoe S. Model-based characterization of dose-response relationship in exploratory clinical development - extracting a small signal from noisy response data [Abstract 64]. ACoP 2008, Tucson, AZ, USA.
- **Wilkins JJ**, Gautier A, Lowe PJ. Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody [poster]. PAGE 17 (2008) Abstr 1284 [www.page-meeting.org/?abstract=1284].
- Karlsson KE, **Wilkins JJ**, Karlsson MO, Jonsson EN. Modelling of disease progression in acute stroke by simultaneously using the NIH stroke scale, the Scandinavian stroke scale and the Barthel index [oral]. PAGE 16 (2007) Abstr 1191 [www.page-meeting.org/?abstract=1191].
- **Wilkins JJ**, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. A flexible approach to modeling variable absorption in the context of repeated dosing: illustrated with rifampicin [oral]. PAGE 16 (2007) Abstr 1113 [www.page-meeting.org/?abstract=1113].
- Armendariz Y, Caldes A, Colom H, Gilvernet S, Peraire C, Domenech J, Grinyó JM, **Wilkins J**, Karlsson MO. Population pharmacokinetics of Valganciclovir in solid organ transplant recipients infected by cytomegalovirus. PAGE 15 (2006) Abstr 1012 [www.page-meeting.org/?abstract=1012]
- Savic RM, **Wilkins JJ**, Karlsson MO. (Un)informativeness of Empirical Bayes Estimate-Based Diagnostics. In: The AAPS Journal; 2006; Vol. 8, No. S2, Abstract T3360
- **Wilkins JJ**, Hooker A, Karlsson MO, Jonsson EN. Xpose – an R-based population pharmacokinetic/pharmacodynamic model-building aid for NONMEM. PAGE 15 (2006) Abstr 1031 [www.page-meeting.org/?abstract=1031]
- **Wilkins J**, Karlsson MO, Jonsson EN. Patterns and power for the visual predictive check [poster]. PAGE 15 (2006) Abstr 1029 [www.page-meeting.org/?abstract=1029].
- Lindbom L, **Wilkins JJ**, Frey N, Karlsson MO, Jonsson EN. Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis [poster]. PAGE 15 (2006) Abstr 997 [www.page-meeting.org/?abstract=997].
- **Wilkins JJ**, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson USH. Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients. PAGE 14 (2005) Abstr 769 [www.page-meeting.org/?abstract=769]
- **Wilkins JJ**, Jonsson F, Zingmark PH, Lyden P, Jonsson EN. Predicting disease progression in acute stroke using the Barthel Index. PAGE 14 (2005) Abstr 744 [www.page-meeting.org/?abstract=744]

- **Wilkins JJ**, Langdon G, McIlhenny H, Pillai G, Smith PJ, Simonsson USH. A population pharmacokinetic-enzyme model for rifampicin autoinduction and bimodal absorption in pulmonary tuberculosis patients. PAGE 13 (2004) Abstr 538 [[www.page-meeting.org/?abstract=538](http://www.page-meeting.org/?abstract=538)]
- Wilder-Smith C, **Wilkins J**. CYP2D6 metabolizer status and postoperative analgesia with tramadol. American Society of Anesthesiologists 1999 annual meeting. Dallas, Texas, USA. October 9-13, 1999. *Anesthesiology* 1999 Sep;91(3A Suppl):U416.